The therapeutic use of osmotic minipumps in the severe combined immunodeficiency (SCID) mouse model for rheumatoid arthritis. 2009

A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
Department of Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Department of Rheumatology and Clinical Immunology, Kerckhoff-Klinik Bad Nauheim, Germany.

OBJECTIVE The viral gene transfer of interleukin 1 receptor antagonist (IL1ra) and interleukin 10 (IL10) into rheumatoid arthritis (RA) synovial fibroblasts (RASFs) has shown protective effects on cartilage destruction in the severe combined immunodeficiency (SCID) mouse model of RA. Nevertheless, side effects of viral transduction are possible and a number of cytokines or cytokine inhibitors are not available encoded in viral vehicles. As the production of viruses coding for bioactive proteins is cost and time intensive, we established an in vivo long-term release model using osmotic minipumps in the SCID mouse model for RA. METHODS Isolated RASFs were cultured for four passages and coimplanted together with human cartilage and an Alzet osmotic miniature pump model 2004, containing 200 microl of IL10 and IL1ra for 40 days in SCID mice. Implants were removed after 40 days and evaluated histologically. The actual rates of IL10 and IL1ra in murine serum were measured by ELISA. RESULTS Release of IL10 and IL1ra by the pumps was effective as both could be measured in significant amounts in the serum of the mice. IL10 and IL1ra release showed protective effects towards the coimplanted cartilage, similar to the adenovirally IL10/IL1ra-transduced RASFs. The mean (SD) invasion scores for the implants with the osmotic pumps were: invasion 0.7 (0.5), degradation 0.5 (0.3) (all parameters significant vs controls, p<0.05). CONCLUSIONS The results demonstrate that the combination of osmotic pumps with the SCID mouse model for RA can be used as approach for application and evaluation of cartilage-protective molecules. Furthermore, the effect of cartilage-protective cytokines is independent of the type of application.

UI MeSH Term Description Entries
D002358 Cartilage, Articular A protective layer of firm, flexible cartilage over the articulating ends of bones. It provides a smooth surface for joint movement, protecting the ends of long bones from wear at points of contact. Articular Cartilage,Articular Cartilages,Cartilages, Articular
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D014161 Transduction, Genetic The transfer of bacterial DNA by phages from an infected bacterium to another bacterium. This also refers to the transfer of genes into eukaryotic cells by viruses. This naturally occurring process is routinely employed as a GENE TRANSFER TECHNIQUE. Genetic Transduction,Genetic Transductions,Transductions, Genetic
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D015918 Infusion Pumps, Implantable Implanted fluid propulsion systems with self-contained power source for providing long-term controlled-rate delivery of drugs such as chemotherapeutic agents or analgesics. Delivery rate may be externally controlled or osmotically or peristatically controlled with the aid of transcutaneous monitoring. Drug Delivery Systems, Implantable,Implantable Infusion Pumps,Perfusion Pumps, Implantable,Peristaltic Pumps, Implantable,Programmable Implantable Medication Systems,Implantable Medication Systems, Programmable,Medication Systems, Programmable Implantable,Systems, Programmable Implantable Medication,Implantable Infusion Pump,Implantable Perfusion Pump,Implantable Perfusion Pumps,Implantable Peristaltic Pump,Implantable Peristaltic Pumps,Infusion Pump, Implantable,Perfusion Pump, Implantable,Peristaltic Pump, Implantable,Pump, Implantable Infusion,Pump, Implantable Perfusion,Pump, Implantable Peristaltic,Pumps, Implantable Infusion,Pumps, Implantable Perfusion,Pumps, Implantable Peristaltic
D016513 Mice, SCID Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice. SCID Mice,SCID-hu Mice,Severe Combined Immunodeficient Mice,Immunodeficient Mice, Severe Combined,Mouse, SCID,Mouse, SCID-hu,Mice, SCID-hu,Mouse, SCID hu,SCID Mouse,SCID hu Mice,SCID-hu Mouse
D016753 Interleukin-10 A cytokine produced by a variety of cell types, including T-LYMPHOCYTES; MONOCYTES; DENDRITIC CELLS; and EPITHELIAL CELLS that exerts a variety of effects on immunoregulation and INFLAMMATION. Interleukin-10 combines with itself to form a homodimeric molecule that is the biologically active form of the protein. IL-10,CSIF-10,Cytokine Synthesis Inhibitory Factor,IL10,Interleukin 10

Related Publications

A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
October 1989, The Journal of experimental medicine,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
November 2021, Revista da Associacao Medica Brasileira (1992),
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
January 1995, Archives of toxicology. Supplement. = Archiv fur Toxikologie. Supplement,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
March 2001, Modern rheumatology,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
January 1993, Regional immunology,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
January 1994, Clinical and experimental rheumatology,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
September 1985, The American journal of pathology,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
April 1995, Scandinavian journal of immunology,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
December 1981, Brain research bulletin,
A Knedla, and B Riepl, and S Lefèvre, and S Kistella, and J Grifka, and R H Straub, and S Gay, and J Schölmerich, and U Müller-Ladner, and E Neumann
October 2002, Blood,
Copied contents to your clipboard!